Boyer, David S.
Rippmann, Joerg F.
Ehrlich, Michael S.
Bakker, Remko A.
Chong, Victor
Nguyen, Quan Dong http://orcid.org/0000-0002-6024-8441
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Received: 1 June 2020
Accepted: 19 February 2021
First Online: 12 April 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: DB is a consultant with Acucela, Alimera Sciences, Allegro, Bayer, EyePoint Pharmaceuticals, ONL Therapeutics, Oxurion, and Takeda; is a consultant and researcher with Adverum, Aerpio Pharmaceuticals, Allergan, Apellis, Boehringer Ingelheim, Chengdu Kanghong, Clearside Biomedical, Genentech/Roche, Kodiak, Novartis, Regeneron, REGENXBIO, Roche, and Santen; and is a researcher with Aerie Pharmaceuticals, Gemini Therapeutics, Graybug Vision, IONIS Pharmaceuticals, Neurotech, Opthea, and Outlook Therapeutics. QDN serves on Scientific Advisory Boards for Aerie Pharmaceuticals, AsclepiX Therapeutics, EyePoint Pharmaceuticals, Bayer, Boehringer Ingelheim, Genentech/Roche, Regeneron, and Santen. QDN is also the Coordinating Investigator of the ROBIN Study. RAB, VC, MSE, and JFR are employees of Boehringer Ingelheim.